Actively Recruiting

Phase 2
Age: 18Years - 130Years
All Genders
NCT06448754

Volrustomig Priming Regimens Exploratory Phase II Platform Study

Led by AstraZeneca · Updated on 2026-05-12

180

Participants Needed

77

Research Sites

152 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

CONDITIONS

Official Title

Volrustomig Priming Regimens Exploratory Phase II Platform Study

Who Can Participate

Age: 18Years - 130Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration
  • Life expectancy of at least 12 weeks
  • Adequate organ and bone marrow function
  • Body weight greater than 35 kilograms at screening and randomization
  • Histologically or cytologically confirmed non-squamous NSCLC in substudy 1 or squamous/non-squamous metastatic NSCLC in substudy 2
  • No sensitizing epidermal growth factor receptor (EGFR) mutations
  • No tumor genomic alterations with approved targeted first-line therapies based on local testing
  • At least one measurable lesion not previously irradiated, at least 10 millimeters in longest diameter at baseline
Not Eligible

You will not qualify if you...

  • Spinal cord compression
  • History of primary active immunodeficiency
  • Active or prior autoimmune or inflammatory disorders
  • Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant
  • Brain metastases unless asymptomatic, stable, and off steroids for at least 14 days before study
  • Less than 2 weeks since end of radiation therapy
  • Prior chemotherapy or systemic therapy for Stage IV NSCLC (prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease allowed if progression occurred more than 12 months after last therapy)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 77 locations

1

Research Site

Los Angeles, California, United States, 90067

Actively Recruiting

2

Research Site

Grand Junction, Colorado, United States, 81501

Actively Recruiting

3

Research Site

Wheat Ridge, Colorado, United States, 80033

Actively Recruiting

4

Research Site

Baltimore, Maryland, United States, 21231

Withdrawn

5

Research Site

Detroit, Michigan, United States, 48202

Withdrawn

6

Research Site

Chapel Hill, North Carolina, United States, 27514

Actively Recruiting

7

Research Site

Tacoma, Washington, United States, 98405

Withdrawn

8

Research Site

Montreal, Quebec, Canada, H4A 3J1

Withdrawn

9

Research Site

Beijing, China, 100730

Actively Recruiting

10

Research Site

Hangzhou, China, 310014

Actively Recruiting

11

Research Site

Jinan, China, 250013

Actively Recruiting

12

Research Site

Yantai, China, 264000

Actively Recruiting

13

Research Site

Zhengzhou, China, 450000

Actively Recruiting

14

Research Site

Bois-Guillaume, France, 76031

Actively Recruiting

15

Research Site

Caen, France, 14076

Actively Recruiting

16

Research Site

Créteil, France, 94000

Withdrawn

17

Research Site

Dijon, France, 21079

Actively Recruiting

18

Research Site

Montpellier, France, 34070

Actively Recruiting

19

Research Site

Batumi, Georgia, 6010

Actively Recruiting

20

Research Site

Tbilisi, Georgia, '0159

Actively Recruiting

21

Research Site

Tbilisi, Georgia, 0112

Actively Recruiting

22

Research Site

Tbilisi, Georgia, 0114

Actively Recruiting

23

Research Site

Tbilisi, Georgia, 0144

Actively Recruiting

24

Research Site

Tbilisi, Georgia, 186

Actively Recruiting

25

Research Site

Athens, Greece, 115 27

Not Yet Recruiting

26

Research Site

Athens, Greece, 12462

Actively Recruiting

27

Research Site

Elaiones, Greece, 546 23

Actively Recruiting

28

Research Site

Piraeus, Greece, 185 47

Actively Recruiting

29

Research Site

Thessaloniki, Greece, 57001

Actively Recruiting

30

Research Site

Genoa, Italy, 16132

Actively Recruiting

31

Research Site

Meldola, Italy, 47014

Actively Recruiting

32

Research Site

Milan, Italy, 20133

Actively Recruiting

33

Research Site

Naples, Italy, 80131

Actively Recruiting

34

Research Site

Orbassano, Italy, 10043

Actively Recruiting

35

Research Site

Perugia, Italy, 06132

Actively Recruiting

36

Research Site

Rozzano, Italy, 20089

Actively Recruiting

37

Research Site

Udine, Italy, 33100

Actively Recruiting

38

Research Site

Verona, Italy, 37134

Actively Recruiting

39

Research Site

Kuala Lumpur, Malaysia, 59100

Actively Recruiting

40

Research Site

Kuching, Malaysia, 93586

Actively Recruiting

41

Research Site

Perai, Malaysia, 13700

Actively Recruiting

42

Research Site

Lisbon, Portugal, 1169-050

Actively Recruiting

43

Research Site

Lisbon, Portugal, 1400-038

Actively Recruiting

44

Research Site

Lisbon, Portugal, 1500-458

Withdrawn

45

Research Site

Lisbon, Portugal, 1649-035

Actively Recruiting

46

Research Site

Porto, Portugal, 4099-001

Actively Recruiting

47

Research Site

Porto, Portugal, 4100-180

Withdrawn

48

Research Site

Cluj-Napoca, Romania, 400641

Actively Recruiting

49

Research Site

Craiova, Romania, 200542

Actively Recruiting

50

Research Site

Floreşti, Romania, 407280

Actively Recruiting

51

Research Site

Belgrade, Serbia, 11000

Withdrawn

52

Research Site

Belgrade, Serbia, 11000

Actively Recruiting

53

Research Site

Kamenitz, Serbia, 21204

Actively Recruiting

54

Research Site

Kragujevac, Serbia, 34000

Actively Recruiting

55

Research Site

Seongnam, South Korea, 13620

Completed

56

Research Site

Seoul, South Korea, 03722

Actively Recruiting

57

Research Site

Seoul, South Korea, 06591

Withdrawn

58

Research Site

Suwon, South Korea, 16247

Actively Recruiting

59

Research Site

A Coruña, Spain, 15009

Actively Recruiting

60

Research Site

Alcorcón, Spain, 28922

Actively Recruiting

61

Research Site

Barcelona, Spain, 08041

Actively Recruiting

62

Research Site

Madrid, Spain, 28041

Actively Recruiting

63

Research Site

Málaga, Spain, 29004

Actively Recruiting

64

Research Site

Pamplona, Spain, 31008

Actively Recruiting

65

Research Site

Santander, Spain, 39008

Actively Recruiting

66

Research Site

Santiago de Compostela, Spain, 15706

Actively Recruiting

67

Research Site

Valencia, Spain, 46015

Actively Recruiting

68

Research Site

Valencia, Spain, 46026

Actively Recruiting

69

Research Site

Basel, Switzerland, 4031

Withdrawn

70

Research Site

Geneva, Switzerland, 1205

Actively Recruiting

71

Research Site

Lausanne, Switzerland, 1011

Actively Recruiting

72

Research Site

Winterthur, Switzerland, 8401

Actively Recruiting

73

Research Site

Zurich, Switzerland, 8091

Actively Recruiting

74

Research Site

Changhua, Taiwan, 50006

Actively Recruiting

75

Research Site

New Taipei City, Taiwan, 23561

Actively Recruiting

76

Research Site

Taipei, Taiwan, 106

Actively Recruiting

77

Research Site

Taipei, Taiwan, 110

Actively Recruiting

Loading map...

Research Team

A

AstraZeneca Clinical Study Information Center

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here